Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1. Patients who participated in CIGE025IA04E1 were perceived by both the patient and the investigator to have benefited from receiving treatment with omalizumab plus current asthma therapy according to best medical practice

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Collaborator: Genentech, Inc.
• Treatments: Omalizumab

Criteria

Inclusion Criteria:

• Patients who completed core study and extension study CIGE24IA05E1 up to and including visit 15, without experiencing any significant drug-related adverse events

• Patients who have given written informed consent

Exclusion Criteria:

• Patients who had not received study medication for greater than 84 days since visit 15 of study CIGE24IA05E1

• Pregnant females or nursing mothers

• Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs

Other protocol-defined inclusion/exclusion criteria may apply.